Aeglea BioTherapeutics Has Agreed To Sell The Global Rights To Pegzilarginase, An Investigational Treatment For The Rare Metabolic Disease Arginase 1 Deficiency To Immedica Pharma For $15M In Upfront Cash And Up To $100M In Contingent Milestone Payments
Portfolio Pulse from Benzinga Newsdesk
Aeglea BioTherapeutics has agreed to sell the global rights to Pegzilarginase, a treatment for the rare metabolic disease Arginase 1 Deficiency, to Immedica Pharma for $15M upfront and up to $100M in contingent milestone payments. This sale supersedes the previous license agreement between Aeglea and Immedica.
July 27, 2023 | 11:18 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aeglea BioTherapeutics has sold the global rights to Pegzilarginase to Immedica Pharma. This could provide a significant cash influx for Aeglea, potentially boosting its stock in the short term.
The sale of Pegzilarginase to Immedica Pharma could provide a significant cash influx for Aeglea BioTherapeutics. This could be used to fund other projects or reduce debt, which could make the company more attractive to investors and potentially boost its stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100